Home Multimedia Podcasts Subvisible Particles in Biotech Drugs Subvisible Particles in Biotech Drugs August 23, 2011 E. Morrey Atkinson, Ph.D., CSO, VP of R&D, Cook Pharmica /wp-content/uploads/2018/09/gencast_082211.mp3 PodcastsResourcesDrug research and developmentPharmacology Also of Interest Gene Network Interactions Shed Insight into Breast Cancer Onset and Development StockWatch: Regeneron Shares Dip as DOJ Alleges Fraudulent Price Reporting Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline Seaport Therapeutics Launches with $100M Series A Blocking Mechanical Squeeze In Asthma Prevents Inflammatory Cycle StockWatch: Investors Less Forgiving than Analysts as Verve Tumbles Related Media Emerging Markets Collaborate to Succeed in Post-Pandemic World Global Single-Use Network Support Assurance of Supply Resins Address Downstream Purification Concerns Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development Moving the Drug Pipeline Forward with Mechanistic Modeling Related Content Gene Network Interactions Shed Insight into Breast Cancer Onset and Development StockWatch: Regeneron Shares Dip as DOJ Alleges Fraudulent Price Reporting Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline Seaport Therapeutics Launches with $100M Series A